Key result
Laboratory testing, including platelet function tests and CYP2C19 genotyping, is summarized for evaluating clopidogrel responsiveness and addressing FDA warnings on genetic polymorphisms.
Design
Review
Authors
Loading...
Laboratory testing summaries address FDA clopidogrel warnings; leaves open whether routine genotyping improves outcomes.
Provides an overview of laboratory and genetic testing methods to evaluate clopidogrel responsiveness in the context of FDA warnings regarding CYP2C19 polymorphisms.
Smock et al. (2011) conducted a review in Clopidogrel responsiveness. Laboratory testing (platelet function tests and CYP2C19 genotyping) was evaluated. Laboratory testing, including platelet function tests and CYP2C19 genotyping, is summarized for evaluating clopidogrel responsiveness and addressing FDA warnings on genetic polymorphisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: